Company Encyclopedia
View More
name
Chunli Medical
688236.SH
Beijing Chunlizhengda Medical Instruments Co., Ltd. engages in the research and development, production, and trading of surgical implants, instruments, and related products in the People’s Republic of China. The company offers implantable orthopedic medical devices, joints, dentures, spine, sports medicine, trauma and orthopedic surgical instruments. It sells its products through distributors, or on ODM and OEM bases, as well as to hospitals directly.
879.67 B
688236.SHMarket value -Rank by Market Cap -/-

Financial Score

11/12/2025 Update
B
Health Care EquipmentIndustry
Industry Ranking13/63
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE8.84%B
    • Profit Margin24.24%A
    • Gross Margin77.63%A
  • Growth ScoreB
    • Revenue YoY13.95%B
    • Net Profit YoY61.27%B
    • Total Assets YoY1.30%C
    • Net Assets YoY6.79%B
  • Cash ScoreB
    • Cash Flow Margin412.61%C
    • OCF YoY13.95%B
  • Operating ScoreD
    • Turnover0.3D
  • Debt ScoreA
    • Gearing Ratio15.65%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Understanding the Market | Chunli Medical rises over 9% again, overseas business has become an important source of income, and third-quarter performance has grown rapidly year-on-year

    CHUNLI MEDICAL's stock price rose over 9% again, with a cumulative increase of nearly 25% after the earnings report. As of the time of writing, the stock price is HKD 20.44, with a trading volume of HKD 98.2915 million. The company's operating revenue for the first three quarters was RMB 756 million, a year-on-year increase of 48.75%; net profit was RMB 192 million, a year-on-year increase of 213.21%. The operating revenue for the third quarter was RMB 268 million, a year-on-year increase of 109.51%. Huatai Securities believes that overseas business has become an important source of revenue and expects it to continue to grow rapidly in the future, maintaining a "Buy" rating

    Zhitong·
    SH
    688236
    -0.54%
    HK
    01858
    -2.59%
    Zhitong·
    SH
    688236
    -0.54%
    HK
    01858
    -2.59%

    The impact of centralized procurement has dissipated, and the stock price of Chunli Medical has risen over 120% this year. Where will it head after three months of consolidation?

    CHUNLI MEDICAL recently released its performance for the first three quarters of 2025, with operating revenue of 756 million yuan, a year-on-year increase of 48.75%; net profit of 192 million yuan, a year-on-year increase of 213.21%. Affected by centralized procurement, the company's revenue in the third quarter of 2024 declined by 49.03% year-on-year, but with the end of inventory adjustments, performance has rebounded significantly. The stock price has risen by 122.13% this year

    Zhitong·
    SH
    688236
    -0.54%
    HK
    01858
    -2.59%
    Zhitong·
    SH
    688236
    -0.54%
    HK
    01858
    -2.59%

    Understanding the Market | Chunli Medical rose over 10%, turning a profit of 77.0619 million yuan in the third quarter as the company actively expands its international market business

    CHUNLI MEDICAL's stock price rose by more than 10%, with an increase of 10.66% as of the time of publication, reported at HKD 18.37, with a transaction volume of HKD 45.461 million. The company released its performance for the first three quarters of 2025, with operating revenue of 756 million yuan, a year-on-year increase of 48.75%; net profit attributable to the parent company of 192 million yuan, a year-on-year increase of 213.21%. In the third quarter, it achieved operating revenue of 268 million yuan, a year-on-year increase of 109.51%; net profit attributable to the parent company of 77.0619 million yuan, turning a profit. Huatai Securities pointed out that the company is actively expanding its international market, with rapid growth in overseas revenue, which has become an important source of income

    Zhitong·
    SH
    688236
    -0.54%
    HK
    01858
    -2.59%
    Zhitong·
    SH
    688236
    -0.54%
    HK
    01858
    -2.59%

    CHUNLI MEDICAL released its performance for the first three quarters, with a net profit attributable to the parent company of 192 million yuan, a year-on-year increase of 213.21%

    According to the Zhitong Finance APP, Chunli Medical released its performance for the first three quarters of 2025, with the group achieving operating revenue of 756 million yuan, a year-on-year increase of 48.75%; the net profit attributable to shareholders of the listed company was 192 million yuan, a year-on-year increase of 213.21%. The basic earnings per share were 0.5 yuan

    Zhitong·
    SH
    688236
    -0.54%
    HK
    01858
    -2.59%
    Zhitong·
    SH
    688236
    -0.54%
    HK
    01858
    -2.59%

    CHUNLI MEDICAL: Plans to distribute cash of 80.2602 million yuan in the first three quarters of 2025

    CHUNLI MEDICAL announced that in the first three quarters of 2025, the company achieved a net profit attributable to shareholders of 192 million yuan. The company plans to distribute a cash dividend of 2.10 yuan for every 10 shares to all shareholders. As of September 30, 2025, the actual number of shares participating in the profit distribution is 382 million shares, with a total cash dividend of 80.2602 million yuan, accounting for 41.90% of the net profit. The company will not increase its capital reserve to convert into share capital and will not issue bonus shares. This plan is subject to approval at the company's first extraordinary general meeting of shareholders in 2025

    Zhitong·
    SH
    688236
    -0.54%
    HK
    01858
    -2.59%
    Zhitong·
    SH
    688236
    -0.54%
    HK
    01858
    -2.59%
    © 2025 Longbridge｜Disclaimer